喹波地匹与他汀类联合方案治疗成人肺结核的安全性、药代动力学及早期杀菌活性:随机、阳性对照、开放标签试验
这项在南非两个研究中心开展的开放标签、阳性对照、随机平行组2期试验,纳入46例药物敏感肺结核成人,评估喹波地匹(quabodepistat)30 mg联合地拉马尼(delamanid)300 mg、贝达喹啉(bedaquiline)400 mg或两者联用14天的安全性、药代动力学和早期杀菌活性(EBA),对照组为利福平、异烟肼、乙胺丁醇和吡嗪酰胺联合治疗20天。结果显示联合方案总体安全、耐受良好,喹波地匹联合地拉马尼和贝达喹啉三药方案第14天痰菌log10 CFU/mL较基线平均下降-2.73(SD 1.51),对照组为-2.71(SD 0.92);作者认为该三药联合方案似乎安全、耐受良好并提供稳健的早期杀菌活性,但需进一步评估。
要点
- 喹波地匹30 mg联合地拉马尼300 mg和贝达喹啉400 mg每日一次口服14天,在药物敏感肺结核成人中似乎安全、耐受良好。
- 三药联合组第14天痰菌log10 CFU/mL较基线平均下降-2.73(SD 1.51;n=12),对照组为-2.71(SD 0.92;n=19)。
- 44例接受至少一剂研究药物的参与者中32例(73%)发生至少一次治疗中出现的不良事件,多数(30/32 [94%])为轻或中度。
核心结论
- 在这项14天试验中,喹波地匹联合地拉马尼和贝达喹啉这一新型三药方案在药物敏感肺结核成人中似乎安全、耐受良好,并提供稳健的早期杀菌活性。
- 作者认为需进一步评估。
研究设计与样本
- 开放标签、阳性对照、随机、平行组研究第2阶段,在南非两个研究中心开展。
- 纳入46例药物敏感肺结核成人(18-64岁),随机分配至四个治疗组,比例14:14:14:4;44例接受至少一剂研究药物。
- 干预组为喹波地匹30 mg联合地拉马尼300 mg、喹波地匹30 mg联合贝达喹啉400 mg、或喹波地匹30 mg联合地拉马尼300 mg和贝达喹啉400 mg,每日一次口服14天;对照组为利福平、异烟肼、乙胺丁醇和吡嗪酰胺联合治疗20天(按当地标准治疗)。
- 主要结局为安全性和耐受性(所有接受任何研究药物的参与者)及药代动力学(喹波地匹组第1天和第14天);主要次要结局为基线至第14天杀菌活性(基线定量培养阳性的合格参与者)。
- 研究未针对正式统计假设检验进行把握度计算,数据按治疗组描述性统计总结。
主要发现
- 44例接受至少一剂研究药物的参与者中,32例(73%)发生至少一次治疗中出现的不良事件;多数事件(30/32 [94%])为轻或中度。
- 最常见治疗中出现的不良事件(≥2例参与者;与研究药物无关)为头痛(4/44 [9%])、头晕(3/44 [7%])、腹痛(2/44 [5%])、瘙痒(2/44 [5%])和恶心(2/44 [5%])。
- 喹波地匹联合贝达喹啉队列报告2例严重不良事件(肛周脓肿[n=1]、气胸[n=1]),均判定与研究药物无关。
- 喹波地匹暴露受地拉马尼或贝达喹啉联用影响极小,喹波地匹联合贝达喹啉队列暴露较低(最大血浆浓度:喹波地匹联合地拉马尼208 ng/mL [SD 61; n=11];喹波地匹联合贝达喹啉175 ng/mL [31; n=10];喹波地匹联合地拉马尼和贝达喹啉183 ng/mL [52; n=11]);所有联合方案中喹波地匹最大浓度约在给药后3小时达到;含贝达喹啉联合方案的平均消除半衰期较短(12.3-14.5 h vs 15.2 h)。
- 第14天痰菌log10 CFU/mL较基线平均变化:喹波地匹联合地拉马尼和贝达喹啉组-2.73(SD 1.51;n=12),对照组-2.71(SD 0.92;n=19);喹波地匹联合地拉马尼组-2.17(SD 1.83;n=11),喹波地匹联合贝达喹啉组-1.97(SD 1.29;n=11)。
关键数值与推荐
- 纳入标准:药物敏感肺结核成人(18-64岁),BMI 16-32 kg/m2,能产生足够痰量(≥10 mL过夜);排除耐药结核或过去3年内接受过结核分枝杆菌治疗者。
- 给药方案:喹波地匹30 mg联合地拉马尼300 mg、喹波地匹30 mg联合贝达喹啉400 mg、或喹波地匹30 mg联合地拉马尼300 mg和贝达喹啉400 mg,每日一次口服14天;对照组为利福平、异烟肼、乙胺丁醇和吡嗪酰胺联合治疗20天(按当地标准治疗)。
- 主要结局:安全性和耐受性(所有接受任何研究药物的参与者)及药代动力学(喹波地匹组第1天和第14天)。
- 主要次要结局:基线至第14天杀菌活性(基线定量培养阳性的合格参与者)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为喹波地匹联合地拉马尼和贝达喹啉三药方案在药物敏感肺结核成人中似乎安全、耐受良好并提供稳健的早期杀菌活性,需进一步评估。
局限性
- 研究未针对正式统计假设检验进行把握度计算;数据按治疗组描述性统计总结。
- 作者认为需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quabodepistat (formerly OPC-167832) showed potent activity in preclinical studies and in the first stage of an early bactericidal activity study in adults with smear-positive, drug-susceptible pulmonary tuberculosis. Stage 2 of this study was designed to evaluate the safety, tolerability, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both versus rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy for 14 days. METHODS: Stage 2 of this open-label, active-controlled, randomised, parallel-group study was conducted at two research sites in South Africa in adults (aged 18-64 years) with drug-susceptible pulmonary tuberculosis. Eligible participants had a BMI of 16-32 kg/m2 and the ability to produce an adequate volume of sputum (≥10 mL overnight) and were excluded if they had drug-resistant tuberculosis or previous treatment for Mycobacterium tuberculosis within the past 3 years. Participants were centrally randomly assigned via interactive web response technology system, with no stratification, into four treatment groups in a ratio of 14:14:14:4 (quabodepistat 30 mg plus delamanid 300 mg, quabodepistat 30 mg plus bedaquiline 400 mg, or quabodepistat 30 mg plus delamanid 300 mg plus bedaquiline 400 mg orally once daily for 14 days, or rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy [control] according to local standard of care for 20 days). The primary outcomes were safety and tolerability during and after 14 days of treatment in all participants who received any study medication and pharmacokinetics at day 1 and day 14 in participants in the quabodepistat groups with adequate data for deriving pharmacokinetics parameters. The main secondary outcome was bactericidal activity from baseline to day 14 in all eligible participants who were quantitatively culture-positive at baseline. The study was not powered for formal statistical hypothesis testing; therefore, data were summarised by treatment group with descriptive statistics. This study is registered with ClinicalTrials.gov (NCT03678688) and is closed to new participants. FINDINGS: 98 participants were screened for entry into stage 2 of the trial between Feb 1, 2021, and Jan 27, 2022, of whom 46 were randomly assigned (14 to each quabodepistat group, 4 to the control group) and 44 received at least one dose of study medication (one patient excluded from the quabodepistat plus delamanid and quabodepistat plus bedaquiline groups). 32 (73%) of 44 participants had at least one treatment-emergent adverse event. Most events (30/32 [94%]) were mild or moderate; the most common treatment-emergent adverse events (≥2 participants; not related to study drugs) were headache (4/44 [9%]), dizziness (3/44 [7%]), abdominal pain (2/44 [5%]), pruritus (2/44 [5%]), and nausea (2/44 [5%]). Two serious adverse events were reported in two participants in the quabodepistat and bedaquiline cohort (anal abscess [n=1], pneumothorax [n=1]); both were deemed not related to study drug. Quabodepistat exposure was minimally affected by coadministration of delamanid or bedaquiline, with lower exposure in the quabodepistat and bedaquiline cohorts (maximum plasma concentration for quabodepistat plus delamanid 208 ng/mL [SD 61; n=11]; quabodepistat plus bedaquiline 175 ng/mL [31; n=10]; quabodepistat plus delamanid plus bedaquiline 183 ng/mL [52; n=11]). Maximum quabodepistat concentrations were achieved approximately 3 h after administration in all combinations. Mean elimination half-life was shorter in combinations with bedaquiline than without bedaquiline (12·3-14·5 h vs 15·2 h). Mean changes from baseline to day 14 of sputum log10 colony-forming units per mL were -2·73 (SD 1·51) for quabodepistat plus delamanid plus bedaquiline (n=12) and -2·71 (SD 0·92) for control (n=19); mean change was -2·17 (SD 1·83) in the quabodepistat plus delamanid cohort (n=11) and -1·97 (SD 1·29) in the quabodepistat plus bedaquiline cohort (n=11). INTERPRETATION: In this 14-day trial, quabodepistat plus delamanid plus bedaquiline, a novel three-drug combination, appeared to be safe, well tolerated, and provided robust early bactericidal activity in adults with drug-susceptible pulmonary tuberculosis. Further evaluation is warranted. FUNDING: Otsuka Pharmaceutical Development & Commercialization and the Bill & Melinda Gates Foundation.
引用
- Dawson R, Diacon AH, De Jager V, et al. Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial. Lancet Infect Dis. 2024. PMID: 39612928. doi:10.1016/S1473-3099(24)00601-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。